Navigation Links
Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
Date:8/3/2009

MORRISTOWN, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Applications (ANDAs) for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths. Metoprolol succinate extended-release tablets are the generic equivalent to AstraZeneca's Toprol XL(R) tablets. Metoprolol succinate extended-release is a beta-blocker used to treat angina, heart failure and high blood pressure. Watson intends to launch the product immediately.

Toprol XL(R) 25 mg and 50 mg and its generic equivalents had annual sales of approximately $628 million for the twelve months ending June 2009, according to IMS sales data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.

Toprol XL(R) is a registered trademark of AstraZeneca PLC.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... Bay, Jamaica (PRWEB) , ... April 30, 2016 ... ... University, and Duane Boise, President and CEO of EMED, today signed a multifaceted ... Jamaica. , EMED and the Northern Caribbean University Department of Natural and Applied ...
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. ... gold in Rio. Under the care of Maximized Living doctors at the London ... unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio ...
(Date:4/29/2016)... ... 2016 , ... In an article published April 16th on the ... and lip injections, which she underwent in order to feel more at home at ... Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is ... even security. Most importantly, employees are the single most important asset in creating ... so unhappy? , Just under half of American workers are emotionally checked out ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
(Date:4/28/2016)... -- TapImmune,Inc. (TPIV), a clinical-stage immune-oncology ... immunotherapeutics and vaccines for the treatment of cancer & metastatic ... Annual Growth Capital Expo to be held on May ... Palace in Las Vegas, Nevada.  The Company presentation will ... by Dr. John N. Bonfiglio a TapImmune ...
Breaking Medicine Technology: